In a report released on January 27, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $50.00. The company’s shares closed last Friday at $41.46.
Bodnar covers the Healthcare sector, focusing on stocks such as SQZ Biotechnologies, Gracell Biotechnologies, and TransCode Therapeutics. According to TipRanks, Bodnar has an average return of -6.8% and a 43.08% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ventyx Biosciences with a $51.14 average price target, a 23.35% upside from current levels. In a report released on January 27, LifeSci Capital also maintained a Buy rating on the stock with a $38.00 price target.
See the top stocks recommended by analysts >>
Based on Ventyx Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $30.46 million. In comparison, last year the company had a GAAP net loss of $12.77 million
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VTYX in relation to earlier this year. Last month, Sandborn William J., the President and Chief Medical Officer of VTYX sold 42,682.00 shares for a total of $1,445,639.34.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Read More on VTYX:
- Ventyx Biosciences remains Best Idea after R&D Day, says Piper Sandler
- Ventyx Biosciences price target raised to $65 from $50 at Evercore ISI
- Ventyx Biosciences announces pipeline updates, strategic priorities
- Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day
- Ventyx Biosciences management to meet with Piper Sandler
